About Lexaria Bioscience Corp. - Common Stock (LEXX)
Lexaria Bioscience Corp is a biotechnology company that focuses on the development of its proprietary drug delivery technology, which enhances the bioavailability of active pharmaceutical ingredients. The company's primary goal is to improve the efficacy and speed of absorption for various compounds, particularly those related to cannabis and nicotine. Through its innovative methods, Lexaria aims to revolutionize the way these substances are consumed, potentially leading to more effective therapeutic outcomes and improved user experiences in the market for both recreational and medicinal products. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 2,000,000 shares of common stock at a purchase price of $1.00 per share in a registered direct offering. The closing of the offering is expected to occur on or about April 28, 2025, subject to the satisfaction of customary closing conditions.
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®
KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders.
